Local immune and barrier changes in eosinophilic esophagitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll adults with active EoE—some who are starting dupilumab or topical budesonide—and non‑EoE controls undergoing upper endoscopy. Researchers will collect esophageal biopsies and measure mucosal barrier function (including transepithelial electrical resistance/TEER and permeability), histology, and local immune markers of type 2 inflammation. In the treatment subgroup, samples will be compared before and during routine therapy to describe local immunological and barrier changes over time. The work aims to clarify local responses that may explain how food triggers start inflammation and why some therapies do not fully restore barrier integrity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

EoE patient group with dupilumab or topical budesonide Previous diagnosis of active EoE confirmed by histopathology e.g. presence of 15 or more eosinophilic granulocytes per hpf in mid or proximal esophageal biopsies Scheduled to start with dupilumab or topical budesonide as regular care 18 to 75 years of age Written informed consent must be obtained and documented

EoE patient group with active EoE Previous diagnosis of active EoE confirmed by histopathology e.g. presence of 15 or more eosinophilic granulocytes per hpf in mid or proximal esophageal biopsies Scheduled for an upper endoscopy 18 to 75 years of age Written informed consent must be obtained and documented

Non-EoE control group Scheduled for a upper endoscopy for other, non-esophageal related, symptoms 18 to 75 years of age Written informed consent must be obtained and documented

Exclusion Criteria:

EoE patient group with dupilumab, topical budesonide and with active EoE Use of oral or systemic antihistaminics, oral cromoglicates, systemic corticosteroids, leukotriene inhibitors or monoclonal antibodies, in the month preceding the study Proven gastroesophageal reflux disease or other cause for esophageal eosinophilia, History of peptic ulcer disease, History of Barrett's esophagus, History of gastro intestinal cancer or ASA class III, IV or V

Non-EoE control group Symptoms suggestive of esophageal disease or other disease that may infolve the esophagus Personal history of atopic, skin or systemic diseases

Where it's running

• Amsterdam UMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Mandy Fijnenberg, WO medicine
• Email: m.fijnenberg@amsterdamumc.nl
• Phone: +316 55946709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of Patient Position on EndoFLIP Measurements in Kids and Young Adults

  This study tests whether EndoFLIP measurements differ when patients are in the supine versus left-side position during the procedure.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07780981

• Natural history of eosinophilic esophagitis in adults and children

  This observational study tests how eosinophilic esophagitis progresses over time in people 5 years and older to understand symptoms and outcomes.

  Recruiting at 2 sites Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia and 1 other locations · NCT07614633

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• Partial enteral nutrition with a dairy-free diet for eosinophilic esophagitis

  This study tests whether partial enteral nutrition plus a dairy-free diet can bring remission and change immune responses, gut bacteria, and toxin levels in children and young adults with eosinophilic esophagitis.

  Recruiting Kate Farms Inc · Seattle, Washington · NCT07234825

• Dupilumab for young children with eosinophilic esophagitis (food-pipe inflammation)

  This study will test whether 24 weeks of dupilumab helps infants and toddlers with active eosinophilic esophagitis improve feeding and reduce esophageal inflammation.

  Recruiting at 13 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 12 other locations · NCT07112378

• Effect of Dupilumab on Esophageal Muscle Function in Eosinophilic Esophagitis

  This study is testing if Dupilumab can help improve the muscle function in the esophagus of people with Eosinophilic Esophagitis.

  Recruiting Phase 4 University of California, San Diego · La Jolla, California · NCT06665971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.